{"name":"Institut de cancérologie Strasbourg Europe","slug":"institut-de-canc-rologie-strasbourg-europe","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Administration of L-TC","genericName":"Administration of L-TC","slug":"administration-of-l-tc","indication":"Cancer (specific indication not publicly specified)","status":"phase_3"},{"name":"Paclitaxel + Trastuzumab","genericName":"Paclitaxel + Trastuzumab","slug":"paclitaxel-trastuzumab","indication":"Adjuvant treatment of node-positive breast cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Thero2-01S22","genericName":"Thero2-01S22","slug":"thero2-01s22","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Administration of L-TC","genericName":"Administration of L-TC","slug":"administration-of-l-tc","phase":"phase_3","mechanism":"L-TC is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells.","indications":["Cancer (specific indication not publicly specified)"],"catalyst":""},{"name":"Paclitaxel + Trastuzumab","genericName":"Paclitaxel + Trastuzumab","slug":"paclitaxel-trastuzumab","phase":"phase_3","mechanism":"Paclitaxel works by inhibiting microtubule dynamics, thereby inducing cell cycle arrest and apoptosis in rapidly dividing cancer cells. Trastuzumab targets the HER2/neu receptor, which is overexpressed in certain breast cancer cells, and triggers antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.","indications":["Adjuvant treatment of node-positive breast cancer","First-line treatment of HER2-positive metastatic breast cancer"],"catalyst":""},{"name":"Thero2-01S22","genericName":"Thero2-01S22","slug":"thero2-01s22","phase":"phase_3","mechanism":"Thero2-01S22's mechanism is unknown.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQQnAwMHJCbzNCeGk0b2psdl9ObGlzWnRWYVdja1ZWRmdReEYwYld0UXBhVDNPQ0RWRUtLRGt6RWVHZi1DVS1OdThfcE9yazQxeGxEaDVZbTloMEpILTZGR3RROHVmNmZqUlg1NGlaVjBBOW0yeVBkLVA2OXI4WmF1VTVBenZ4cFcxMnd4UWxQTktoWU40S1RSdC1QdDF0MGlVWmxWb25JUTlVX3ZB?oc=5","date":"2025-07-03","type":"pipeline","source":"Medscape","summary":"Efficacy and Toxicity Seen With MIRV in Ovarian Cancer - Medscape","headline":"Efficacy and Toxicity Seen With MIRV in Ovarian Cancer","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}